FY2025 · ended Dec 31, 2025 · Revenue $149.50M, -0.3% YoY · Filed Mar 9, 2026
Macrogenics, Inc. (MGNX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $149.5 million and a net loss of $74.6 million. Free cash flow was -$83.0 million. As of Jun 30, 2026 it held $173.3 million in cash and investments and $35.1 million in total debt.
Revenue (TTM)
$175.14M
+21.7% vs year-ago TTM
Net income (TTM)
$-14.59M
+59.9% vs year-ago TTM
Operating cash flow (TTM)
$-63.72M
+11.6% vs year-ago TTM
Free cash flow (TTM)
$-65.54M
+12.1% vs year-ago TTM
EPS (TTM)
$-0.23
+60.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
63.56M
+0.7% vs prior year
Net cash
$138.21M
as of Jun 30, 2026
Operating margin
-21.7%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MGNX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Rockville, MD
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1125345
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $149.5M | $150.0M | $58.7M | $151.9M | $77.4M |
| Operating income | -$72.8M | -$110.6M | -$168.2M | -$121.4M | -$202.8M |
| Net income | -$74.6M | -$67.0M | -$9.1M | -$119.8M | -$202.1M |
| Diluted EPS | -$1.18 | -$1.07 | -$0.15 | -$1.95 | — |
| Operating cash flow | -$81.0M | -$68.4M | -$78.2M | -$87.0M | -$143.8M |
| Free cash flow | -$83.0M | -$72.1M | -$80.0M | -$90.6M | -$150.0M |
| Total assets | $256.8M | $261.7M | $298.4M | $280.5M | $335.2M |
| Total liabilities | $201.3M | $145.6M | $145.8M | $138.5M | $95.6M |
| Stockholders' equity | $55.6M | $116.1M | $152.6M | $142.0M | $239.6M |
| Cash and investments | $189.9M | $201.7M | $229.8M | $154.3M | $243.6M |
| Total debt | $36.8M | $37.5M | $34.0M | $34.8M | $25.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Nov 3, 2026 | Oct 30, 2026 |
| 8-K |
Current report
Other events
|
Oct 23, 2026 | Oct 23, 2026 |
| 8-K/A | Amended current report | Sep 3, 2026 | Sep 3, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Other events
|
Jul 23, 2026 | Jul 23, 2026 |
All 944 Macrogenics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.